iTeos Therapeutics, Inc.
ITOS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $35,000 | $12,595 | $267,630 | $344,775 |
| % Growth | 177.9% | -95.3% | -22.4% | – |
| Cost of Goods Sold | $1,238 | $898 | $813 | $615 |
| Gross Profit | $33,762 | $11,697 | $266,817 | $344,160 |
| % Margin | 96.5% | 92.9% | 99.7% | 99.8% |
| R&D Expenses | $145,447 | $113,300 | $97,359 | $59,369 |
| G&A Expenses | $49,081 | $50,396 | $43,947 | $40,505 |
| SG&A Expenses | $49,081 | $50,396 | $43,947 | $40,505 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$1,238 | -$898 | -$813 | -$615 |
| Operating Expenses | $193,290 | $162,798 | $140,493 | $99,259 |
| Operating Income | -$159,528 | -$151,101 | $126,324 | $244,901 |
| % Margin | -455.8% | -1,199.7% | 47.2% | 71% |
| Other Income/Exp. Net | $39,186 | $42,071 | $22,412 | $11,563 |
| Pre-Tax Income | -$120,342 | -$109,030 | $148,736 | $256,464 |
| Tax Expense | $14,072 | $3,612 | $52,084 | $41,943 |
| Net Income | -$134,414 | -$112,642 | $96,652 | $214,521 |
| % Margin | -384% | -894.3% | 36.1% | 62.2% |
| EPS | -3.32 | -3.15 | 2.72 | 6.1 |
| % Growth | -5.4% | -215.8% | -55.4% | – |
| EPS Diluted | -3.32 | -3.15 | 2.56 | 5.68 |
| Weighted Avg Shares Out | 40,474 | 35,764 | 35,552 | 35,181 |
| Weighted Avg Shares Out Dil | 40,474 | 35,764 | 37,767 | 37,775 |
| Supplemental Information | – | – | – | – |
| Interest Income | $30,872 | $31,774 | $11,361 | $78 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1,238 | $898 | $813 | $615 |
| EBITDA | -$121,823 | -$111,659 | $148,377 | $257,079 |
| % Margin | -348.1% | -886.5% | 55.4% | 74.6% |